natgillin/translations-raw huggingface dataset:
The patient should avoid situations where OptiSet may be damaged.
Izogiba naj se okoliščinam, v katerih se OptiSet lahko poškoduje.
The patient should avoid situations where OptiSet may be damaged.
Izogibajte se okoliščinam, v katerih se OptiSet lahko poškoduje.
The patient should avoid situations where SoloStar may be damaged.
Izogiba naj se okoliščinam, v katerih se SoloStar lahko poškoduje.
The patient should avoid situations where SoloStar may be damaged.
Izogibajte se okoliščinam, v katerih se SoloStar lahko poškoduje.
The patient should be adequately hydrated and haemodynamically optimised and adequately anticoagulated (if necessary) prior to administering BRINAVESS
Pred dajanjem zdravila BRINAVESS morajo biti bolniki ustrezno hidrirani in hemodinamsko optimizirani ter (po potrebi) na ustreznem antikoagulantnem zdravljenju.
The patient should be advised not to administer Improvac and/or any other product with similar action in the future.
Pacientu se v prihodnje odsvetuje uporaba Improvac-a in/ali zdravil s podobnim delovanjem.
The patient should be advised not to administer Improvac and/or any other veterinary medicinal products with similar action in the future.
Pacientu se v prihodnje odsvetuje uporaba Improvac-a in/ali zdravil s podobnim delovanjem.
The patient should be advised that in case of sudden visual defect, he should stop taking CIALIS and consult a physician immediately (see section 4.3).
Bolnika je treba opozoriti, da naj v primeru nenadne okvare vida preneha jemati zdravilo CIALIS in o tem nemudoma obvesti svojega zdravnika (glejte poglavje 4.3).
The patient should be advised that in case of sudden visual defect, he should stop taking Tadalafil Mylan and consult a physician immediately (see section 4.3).
Bolnika je treba opozoriti, da naj v primeru nenadne okvare vida preneha jemati zdravilo Tadalafil Mylan in o tem nemudoma obvesti svojega zdravnika (glejte poglavje 4.3).
The patient should be advised that in case of sudden visual defect, to consult a physician immediately (see section 4.3).
Bolnika je treba opozoriti, da naj v primeru nenadne okvare vida preneha jemati zdravilo ADCIRCA, da o tem nemudoma obvesti svojega zdravnika (glejte poglavje 4.3).
The patient should be advised that in the case of sudden visual defect, he should stop taking Levitra and consult immediately a physician (see section 4.3).
Bolnika je treba opozoriti, da naj v primeru nenadne okvare vida preneha jemati zdravilo Levitra in o tem nemudoma obvesti zdravnika (glejte poglavje 4.3).
The patient should be advised that in the case of sudden visual defect, he should stop taking Levitra orodispersible tablets and consult immediately a physician (see section 4.3).
Bolnika je treba opozoriti, da naj v primeru nenadne okvare vida preneha jemati zdravilo Levitra orodisperzibilne tablete in o tem nemudoma obvesti zdravnika (glejte poglavje 4.3).
The patient should be advised that in the case of sudden visual defect, he should stop taking Vivanza and consult immediately a physician (see section 4.3).
Bolnika je treba opozoriti, da naj v primeru nenadne okvare vida preneha jemati zdravilo Vivanza in o tem nemudoma obvesti zdravnika (glejte poglavje 4.3).
The patient should be advised that in the case of sudden visual defect, he should stop taking Vivanza orodispersible tablets and consult immediately a physician (see section 4.3).
Bolnika je treba opozoriti, da naj v primeru nenadne okvare vida preneha jemati zdravilo Vivanza orodisperzibilne tablete in o tem nemudoma obvesti zdravnika (glejte poglavje 4.3).
The patient should be advised to read the instructions for use included in the package leaflet carefully before using ABASAGLAR KwikPen.
Bolnikom je treba svetovati, naj pred uporabo peresnika ABASAGLAR KwikPen natančno preberejo navodila za uporabo na vloženem lističu.
The patient should be advised to read the instructions for use included in the package leaflet carefully before using OptiSet.
Bolniku naj se svetuje, da si pred uporabo natančno prebere navodila za ravnanje z OptiSetom v navodilu za uporabo.
The patient should be advised to read the instructions for use included in the package leaflet carefully before using OptiSet.
Pred uporabo OptiSeta natančno preberite navodila za ravnanje z OptiSetom v navodilu za uporabo.
The patient should be advised to read the instructions for use included in the package leaflet carefully before using SoloStar.
Pred uporabo SoloStarja natančno preberite navodila za ravnanje z injekcijskim peresnikom v navodilu za uporabo.
The patient should be given Instanyl for a maximum of four episodes of breakthrough pain a day.
Bolnik lahko prejme zdravilo Instanyl za največ štiri epizode prebijajoče bolečine na dan.
The patient should be instructed to discard the pen safely, with the needle still attached, after each injection.
Bolniku je potrebno naročiti, naj po vsakem injiciranju peresnik s še vedno nameščeno iglo varno zavrže.
The patient should be instructed to discard the syringe safely, with the needle still attached after each injection.
Bolnika naučite, da brizgo po vsakem injiciranju varno zavrže, pri čemer naj bo igla po injiciranju pritrjena.
The patient should be instructed to do the following:
Bolnika poučite naj:
The patient should be pre-medicated with a bronchodilator 5-15 minutes prior to the initiation dose but after the baseline FEV1 and SpO2 (Oxygen saturation in the blood) measurement.
Bolnik mora dobiti premedikacijo z bronhodilatatorjem 5–15 minut pred začetnim odmerkom, vendar po izhodiščni meritvi FEV1 in SpO2 (nasičenost krvi s kisikom).
The patient should be screened for skin type
Potrebno je preveriti bolnikov tip kože.
The patient should be told not to take two doses at the same time if a dose has been missed.
Bolniku je treba povedati, naj ne vzame dveh odmerkov hkrati, če je enega izpustil.
The patient should continue with a cycle of four weeks ‘on’ treatment followed by four weeks ‘off’
Bolniki morajo nadaljevati s ciklom
The patient should continue with the regular 15 mg twice daily intake as recommended on the following day.
Bolnik naj naslednji dan nadaljuje z rednimi odmerki po 15 mg dvakrat na dan, kot je priporočeno.
The patient should drink this test solution immediately.
Nemudoma jo morate popiti.
The patient should not apply more than one patch at a time.
Bolnik ne sme namestiti več kot enega obliža hkrati.
The patient should not eat for at least six hours, preferably overnight, before taking the test.
Bolnik pred izvajanjem testa ne sme jesti najmanj šest ur, najbolje čez noč.
The patient should not take an extra dose if they do not taste anything after inhaling.
Če bolnik po inhaliranju ne okuša ničesar, naj ne vdihne še enega odmerka.
The patient should sit in an upright position during inhalation.
Bolnik naj med inhaliranjem sedi vzravnano.
The patient should take 0.5 ml solution (5 mg) equivalent to one pump actuation per day for 7 days.
Bolnik mora sedem dni jemati 0.5 ml raztopine (5 mg) na dan, kar ustreza enemu pritisku navzdol.
The patient should take 1 ml solution (10 mg) equivalent to two pump actuations per day for 7 days.
Bolnik mora sedem dni jemati 1 ml raztopine (10 mg) na dan, kar ustreza dvema pritiskoma navzdol.
The patient should take 1.5 ml solution (15 mg) equivalent to three pump actuations per day for 7 days.
Bolnik mora sedem dni jemati 1,5 ml raztopine (15 mg) na dan, kar ustreza trem navpičnim pritiskom navzdol.
The patient should take 1.5 ml solution (15 mg) equivalent to three pump actuations per day for 7 days.
Bolnik mora sedem dni jemati 1.5 ml raztopine (15 mg) na dan, kar ustreza trem pritiskom navzdol.
The patient should take 10 mg per day for 7 days.
Bolnik mora sedem dni jemati eno 10 mg filmsko obloženo tableto na dan.
The patient should take 15 mg per day for 7 days.
Bolnik mora sedem dni jemati eno 15 mg filmsko obloženo tableto na dan.
The patient should take 2 ml solution (20 mg) equivalent to four pump actuations once a day.
Bolnik mora jemati 2 ml raztopine (20 mg) enkrat na dan, kar ustreza štirim pritiskom navzdol.
The patient should take 2 ml solution (20 mg) equivalent to four pump actuations once a day.
Bolnik mora jemati 2 ml raztopine (20 mg) na dan, kar ustreza štirim pritiskom navzdol,.
The patient should take 5 mg per day for 7 days.
Bolnik mora sedem dni jemati eno 5 mg filmsko obloženo tableto na dan.
The patient should take four 5 mg film-coated tablets (20 mg) per day.
Bolnik mora jemati štiri 5-miligramske filmsko obložene tablete (20 mg) na dan.
The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7 days.
Bolnik mora sedem dni jemati pol 10-miligramske filmsko obložene tablete (5 mg) na dan.
The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7 days.
Bolnik mora sedem dni jemati polovico 10 mg filmsko obložene tablete (5 mg) na dan.
The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7 days.
Bolnik mora sedem dni jemati polovico 10-miligramske filmsko obložene tablete (5 mg) na dan.
The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7 days.
Bolnik naj sedem dni jemlje polovico 10 mg filmsko obložene tablete (5 mg) na dan.
The patient should take half a 10 mg film-coated tablet (5 mg) per day for 7days.
Bolnik naj sedem dni jemlje polovico 10 mg filmsko obložene tablete (5 mg) na dan.
The patient should take one 10 mg film-coated tablet (10 mg) per day for 7 days.
Bolnik mora sedem dni jemati eno 10 mg filmsko obloženo tableto (10 mg) na dan.
The patient should take one 10 mg film-coated tablet (10 mg) per day for 7 days.
Bolnik mora sedem dni jemati eno 10 mg na dan filmsko obloženo tableto (10 mg) na dan.
The patient should take one 10 mg film-coated tablet (10 mg) per day for 7 days.
Bolnik mora sedem dni jemati eno 10-miligramsko filmsko obloženo tableto (10 mg) na dan.
The patient should take one 10 mg film-coated tablet (10 mg) per day for 7 days.
Bolnik naj sedem dni jemlje eno 10 mg na dan filmsko obloženo tableto (10 mg) na dan.
The patient should take one 10 mg film-coated tablet (10 mg) per day for 7days.
Bolnik naj sedem dni jemlje eno 10 mg na dan filmsko obloženo tableto (10 mg) na dan.
The patient should take one 10 mg film-coated tablet per day (pale yellow to yellow, oval shaped) for 7 days.
Bolnik naj 7 dni jemlje eno 10 mg filmsko obloženo tableto na dan (bledo rumena do rumena, ovalna).
The patient should take one 10 mg film-coated tablet per day (white to off-white, capsule shaped, biconvex tablets with a break score on one side and embossed with “10” on the other side.) for 7 days.
Bolnik naj 7 dni jemlje eno 10 mg filmsko obloženo tableto na dan (bele do belkaste, kapsulaste, bikonveksne tablete z razdelilno zarezo na eni strani in napisom »10« na drugi).
The patient should take one 10 mg film-coated tablet per day (white, scored) for 7days.
Bolnik naj 7 dni jemlje eno 10 mg filmsko obloženo tableto na dan (bela z razdelilno zarezo).
The patient should take one 10 mg film-coated tablet per day for 7 days.
Bolnik mora sedem dni jemati eno 10 mg filmsko obloženo tableto na dan.
The patient should take one 10 mg film-coated tablet per day for 7 days.
Bolnik mora sedem dni jemati eno 10-miligramsko filmsko obloženo tableto na dan.
The patient should take one 10 mg film-coated tablet per day for 7 days.
Bolnik naj sedem dni jemlje eno 10 mg filmsko obloženo tableto na dan.
The patient should take one 15 mg film-coated tablet per day (grey-orange, oval-oblong) for 7 days.
Bolnik naj 7 dni jemlje eno 15 mg filmsko obloženo tableto na dan (sivo oranžna, ovalno podolgovata).
The patient should take one 15 mg film-coated tablet per day (greyorange, oval-oblong) for 7 days.
Bolnik naj 7 dni jemlje eno 15 mg filmsko obloženo tableto na dan (sivo oranžna, ovalna in podolgovata).
The patient should take one 15 mg film-coated tablet per day (orange to grey-orange) for 7days.
Bolnik naj 7 dni jemlje eno 15 mg filmsko obloženo tableto na dan (oranžna do sivo oranžna).
The patient should take one 15 mg film-coated tablet per day (orange, oval shaped) for 7 days.
Bolnik mora sedem dni jemati eno 15-miligramsko filmsko obloženo tableto (oranžno, ovalno) na dan.
The patient should take one 15 mg film-coated tablet per day (white to off-white, capsule shaped, biconvex tablets plain on one side and embossed with “15” on the other side.) for 7 days.
Bolnik naj 7 dni jemlje eno 15 mg filmsko obloženo tableto na dan (bele do belkaste, kapsulaste, bikonveksne tablete, ravne na eni strani in z napisom »15« na drugi).
The patient should take one 15 mg film-coated tablet per day for 7 days.
Bolnik mora sedem dni jemati eno 15 mg filmsko obloženo tableto na dan.
The patient should take one 15 mg film-coated tablet per day for 7 days.
Bolnik mora sedem dni jemati eno 15-miligramsko filmsko obloženo tableto na dan.
The patient should take one 15 mg film-coated tablet per day for 7 days.
Bolnik naj sedem dni jemlje eno 15 mg filmsko obloženo tableto na dan.
The patient should take one 20 mg film-coated tablet (20 mg) per day.
Bolnik mora jemati eno 20 mg filmsko obloženo tableto na dan.
The patient should take one 20 mg film-coated tablet (20 mg) per day.
Bolnik mora jemati eno 20-miligramsko filmsko obloženo tableto (20 mg) na dan.
The patient should take one 20 mg film-coated tablet per day (grey-red, oval-oblong) for 7 days.
Bolnik naj 7 dni jemlje eno 20 mg filmsko obloženo tableto na dan (sivo rdeča, ovalna in podolgovata).
The patient should take one 20 mg film-coated tablet per day (grey-red, oval-oblong) for 7 days.
Bolnik naj 7 dni jemlje eno 20 mg filmsko obloženo tableto na dan (sivo rdeča, ovalno podolgovata).
The patient should take one 20 mg film-coated tablet per day (pale red to grey-red, scored) for 7 days.
Bolnik naj 7 dni jemlje eno 20 mg filmsko obloženo tableto na dan (bledo rdeča do sivo rdeča z razdelilno zarezo).
The patient should take one 20 mg film-coated tablet per day (white to off-white, capsule shaped, biconvex tablets with a break score on one side and embossed with “20” on the other side.) for 7 days.
Bolnik naj 7 dni jemlje eno 20 mg filmsko obloženo tableto na dan (bele do belkaste, kapsulaste, bikonveksne tablete z razdelilno zarezo na eni strani in napisom »20« na drugi).
The patient should take one 20 mg film-coated tablet per day for 7 days.
Bolnik naj jemlje eno 20 mg filmsko obloženo tableto na dan.
The patient should take one 20 mg film-coated tablet per day.
Bolnik mora jemati eno 20-miligramsko filmsko obloženo tableto na dan.
The patient should take one 20 mg film-coated tablet per day.
Bolnik mora sedem dni jemati eno 20 mg filmsko obloženo tableto na dan.
The patient should take one 20 mg film-coated tablet per day.
Bolnik naj jemlje eno 20 mg filmsko obloženo tableto na dan.
The patient should take one 5 mg film-coated tablet (5 mg) per day for 7 days.
Bolnik mora sedem dni jemati eno 5-miligramsko filmsko obloženo tableto (5 mg) na dan.
The patient should take one 5 mg film-coated tablet per day (white to off-white, capsule shaped, biconvex tablets plain on one side and embossed with “5” on the other side) for 7 days.
Bolnik naj 7 dni jemlje eno 5 mg filmsko obloženo tableto na dan (bele do belkaste, kapsulaste, bikonveksne tablete, ravne na eni strani in z napisom »5« na drugi).
The patient should take one 5 mg film-coated tablet per day (white to off-white, oval-oblong) for 7 days.
Bolnik naj 7 dni jemlje eno 5 mg filmsko obloženo tableto na dan (bela do belkasta, ovalna in podolgovata).
The patient should take one 5 mg film-coated tablet per day (white to off-white, oval-oblong) for 7 days.
Bolnik naj 7 dni jemlje eno 5 mg filmsko obloženo tableto na dan (bela do belkasta, ovalno podolgovata).
The patient should take one 5 mg film-coated tablet per day (white) for 7days.
Bolnik naj 7 dni jemlje eno 5 mg filmsko obloženo tableto na dan (bela).
The patient should take one 5 mg film-coated tablet per day (white, oval-shaped) for 7 days.
Bolnik mora sedem dni jemati eno 5-miligramsko filmsko obloženo tableto (belo ovalno) na dan.
The patient should take one 5 mg film-coated tablet per day for 7 days.
Bolnik mora sedem dni jemati eno 5 mg filmsko obloženo tableto na dan.
The patient should take one 5 mg film-coated tablet per day for 7 days.
Bolnik mora sedem dni jemati eno 5-miligramsko filmsko obloženo tableto na dan.
The patient should take one 5 mg film-coated tablet per day for 7 days.
Bolnik naj sedem dni jemlje eno 5 mg filmsko obloženo tableto na dan.
The patient should take one and a half 10 mg film-coated tablet (15 mg) per day for 7 days.
Bolnik naj sedem dni jemlje eno in pol 10 mg filmsko obloženo tableto (15 mg) na dan.
The patient should take one and a half 10 mg film-coated tablet (15 mg) per day for 7days.
Bolnik naj sedem dni jemlje eno in pol 10 mg filmsko obloženo tableto (15 mg) na dan.
The patient should take one and a half 10 mg film-coated tablet (15 mg)per day for 7 days.
Bolnik mora sedem dni jemati eno in pol 10 mg filmsko obloženo tableto (15 mg) na dan.
The patient should take one and a half 10 mg film-coated tablets (15 mg) per day for 7 days.
Bolnik mora sedem dni jemati eno 10-miligramsko filmsko obloženo tableto in pol (15 mg) na dan.
The patient should take one and a half 10 mg film-coated tablets (15 mg) per day for 7 days.
Bolnik mora sedem dni jemati eno in pol 10 mg filmsko obloženo tableto (15 mg) na dan.
The patient should take one and a half 10 mg film-coated tablets (15 mg) per day for 7 days.
Bolnik mora sedem dni jemati eno in pol 10-miligramske filmsko obložene tablete (15 mg) na dan.
The patient should take one and a half 10 mg film-coated tablets (15 mg) per day for 7 days.
Bolnik mora sedem dni jemati eno in pol 10-miligramsko filmsko obloženo tableto (15 mg) na dan.
The patient should take one Selincro tablet by mouth ‘as needed’, which means when there is a risk that they would start drinking.
Bolnik mora vzeti eno tableto zdravila Selincro peroralno „po potrebi“, tj. ko obstaja tveganje, da bi bolnik začel piti alkohol.
The patient should take three 5 mg film-coated tablets (15 mg) per day for 7 days.
Bolnik mora sedem dni jemati tri 5-miligramske filmsko obložene tablete (15 mg) na dan.
The patient should take two 10 mg film-coated tablets (20 mg) per day.
Bolnik mora jemati dve 10 mg filmsko obloženi tableti (20 mg) na dan.
The patient should take two 10 mg film-coated tablets (20 mg) per day.
Bolnik mora jemati dve 10-miligramski filmsko obloženi tableti (20 mg) na dan.
The patient should take two 10 mg film-coated tablets (20 mg) per day.
Bolnik naj jemlje dve 10 mg filmsko obloženi tableti (20 mg) na dan.
The patient should take two 10 mg film-coated tablets (20mg) per day.
Bolnik mora jemati dve 10 mg filmsko obloženi tableti (20 mg) na dan.
The patient should take two 5 mg film-coated tablets (10 mg) per day for 7 days.
Bolnik mora sedem dni jemati dve 5-miligramski filmsko obloženi tableti (10 mg) na dan.
The patient should then be instructed to self-perform penile modeling activities at home each day for the 6-week period following the physician penile plaque modeling visit of each treatment cycle, according to the detailed instructions provided in the package leaflet.
Bolniku je treba dati navodila za samoizvajanje aktivnosti modeliranja penisa doma, vsak dan za obdobje 6 tednov po obisku vsakega cikla zdravljenja, na katerem zdravnik opravi modeliranje plaka penisa, v skladu s podrobnimi navodili v navodilu za uporabo.
The patient then undergoes the procedures for radionuclide myocardial perfusion imaging, starting with an injection of a radioactive substance 10 to 20 seconds
Pri bolniku se nato izvede postopek radionuklidnega slikanja miokardne perfuzije, ki se začne z injiciranjem radioaktivne snovi 10 do 20 sekund po injiciranju natrijevega klorida.
The patient year adjusted incidence of ONJ was 0.2% during the first year of treatment and 1.7% in the second year.
Incidenca osteonekroze čeljustnice, korigirana za bolnik-leta, je bila prvo leto zdravljenja 0,2 % in drugo leto 1,7 %.
The patient's BSA must be recalculated and the Teysuno dose adjusted accordingly if a patient’s weight increases or decreases by ≥10% from the one used for the previous calculation of BSA and the change is clearly not related to fluid retention.
BSA bolnika se mora preračunati, odmerek zdravila Teysuno pa ustrezno prilagoditi, če se bolnikova masa poveča ali zmanjša za ≥10 % glede na maso, ki se je uporabila za predhodni izračun BSA, in če sprememba zagotovo ni povezana z zastajanjem tekočine.
the patient's life-style changes, other circumstances arise that may promote an increased susceptibility to hypo- or hyperglycaemia (see section 4.4).
premeni bolnikov življenjski slog, pojavijo druge okoliščine, ki lahko sprožijo večjo nagnjenost k hipo- ali hiperglikemiji (glejte poglavje 4.4).
the patient's life-style changes, other circumstances arise that may promote an increased susceptibility to hypo- or hyperglycaemia (see section 4.4).
če se spremeni bolnikov življenjski slog, če se pojavijo druge okoliščine, ki lahko sprožijo večjo nagnjenost k hipo- ali hiperglikemiji (glejte poglavje 4.4).
the patient's weight changes,
premeni bolnikova telesna masa,
the patient's weight changes,
če se spremeni bolnikova telesna masa,
The patient-specific pack contains a variable number of casings based on the patient’s body weight.
Za bolnika specifično pakiranje vsebuje različno število ovojev, ki je odvisno od bolnikove telesne mase.
The patient-year adjusted overall incidence of confirmed ONJ was 1.1% during the first year of treatment, 3.7% in the second year and 4.6% per year thereafter.
Celotna, za bolnik-leta korigirana incidenca potrjene osteonekroze čeljustnice je bila 1,1 % v prvem letu zdravljenja, 3,7 % v drugem letu in 4,6 % na leto pozneje.
The patient/caregiver is to be instructed to follow the directions below:
Bolniku/negovalcu je treba naročiti, naj upošteva spodnja navodila:
The Patient/carer and close contacts guide shall contain the following key messages:
Vodnik za bolnika/negovalca in osebe, ki so v tesnem stiku z bolnikom mora vsebovati sledeča ključna sporočila:
The Patient/Carer educational material shall contain the following key messages: the risk of hepatotoxicity associated with the use of Jinarc the importance of pregnancy prevention, before and during treatment with Jinarc
Izobraževalno gradivo za bolnika/negovalca mora vsebovati naslednja ključna sporočila: tveganje hepatotoksičnosti, povezane z uporabo zdravila Jinarc pomen preprečevanja nosečnosti pred zdravljenjem z zdravilom Jinarc in med njim
The Patient/parents or caregivers guides shall contain the following key messages:
Navodila za bolnike/starše ali skrbnike bodo vsebovala naslednja ključna sporočila:
The patients assessed the severity of their symptoms using a standard questionnaire.
Bolniki so resnost svojih simptomov ocenjevali s pomočjo standardnega vprašalnika.
The patients at risk of TLS and TFR are those with high tumour burden prior to treatment.
Bolniki s tveganjem za sindrom tumorske lize in reakcijo izbruha tumorja so tisti, ki imajo pred zdravljenjem veliko tumorsko breme.
The patients can inject Avonex themselves if they have been trained appropriately.
Bolniki si lahko zdravilo Avonex injicirajo sami, če so bili za to ustrezno usposobljeni.
The patients can inject Betaferon themselves, provided that they have been trained.
Bolniki si lahko zdravilo Betaferon injicirajo sami, če so bili ustrezno usposobljeni.
The patients can inject Extavia themselves, provided that they have been trained.
Bolniki lahko zdravilo Extavia injicirajo sami, če so bili za to ustrezno usposobljeni.
The patients can inject Rebif themselves if they have been trained appropriately.
Bolniki si lahko zdravilo Rebif injicirajo sami, če so bili za to ustrezno usposobljeni.
The patients cannot tell whether they received Lucentis or the sham procedure.
Bolniki zato ne vedo, ali so prejeli zdravilo Lucentis ali placebo.
The patients continued to receive their standard treatments for SLE during the studies.
V času študij so se bolniki še naprej zdravili z običajnimi zdravili proti sistemskemu eritematoznemu lupusu.